Tuberculosis treatment trial for new patients
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have active tuberculosis confirmed by symptoms, imaging, and a lab test.
- You have not received any tuberculosis treatment before.
- You are willing to have HIV testing and provide samples for research.
- If you are a woman who could become pregnant, you must have a negative pregnancy test and agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a very short treatment for active lung TB in people aged 65 and older. The goal is to see if a short course of medicines can effectively cure TB without side effects.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.
This Phase 3 trial tests an oral medicine (Sudapyridine/WX-081) to treat people with rifampicin-resistant pulmonary tuberculosis. It compares how well the study drug works when you stop prior tuberculosis medicines and go through a short “washout” period first.
Hear when a new Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.